# TenNor Therapeutics Reports Positive Phase IIa POC Data for Rifaquizinone (TNP-2092), the First Non-Surgical Therapy Candidate for Periprosthetic Joint Infection

- Link: https://www.thailand-business-news.com/pr-news/tennor-therapeutics-reports-positive-phase-iia-poc-data-for-rifaquizinone-tnp-2092-the-first-non-surgical-therapy-candidate-for-periprosthetic-joint-infection
- Published: 2026-09-10T18:30:00+07:00
- Author: PR Newswire

**— Phase IIb multicenter trial initiated, bringing this potential life-changing
therapy closer to patients —**

SUZHOU, China, Sept. 10, 2026 /PRNewswire/ — TenNor Therapeutics, a near-commercial-
stage biotechnology company, today announced positive topline results from a Phase
IIa proof-of-concept (POC) trial of rifaquizinone (TNP-2092), a first-in-class, 
triple-targeting drug candidate administered via intra-articular (IA) injection 
for the treatment of periprosthetic joint infection (PJI). The data suggest that
TNP-2092 has the potential to cure PJI without surgical intervention—a paradigm 
shift that could fundamentally transform patient outcomes. Based on the findings,
the company has initiated a multicenter Phase IIb trial to accelerate clinical development.

**The Unmet Need in PJI**

PJI is a devastating complication that can turn a successful joint arthroplasty 
into a medical and personal crisis. Approximately 45,000 new cases occur annually
in the U.S. and 22,000 in China, yet treatment remains exceptionally challenging
due to bacterial biofilm formation, which largely undermines the efficacy of conventional
antibiotics. Surgical intervention is considered essential, as antibiotic‑only regimens
carry unacceptably high failure rates.

Patients currently face suboptimal surgical pathways: debridement, antibiotics, 
and implant retention (DAIR) for early postoperative (early) or acute hematogenous(
acute) PJIs—with reported failure rates exceeding 30%—or a two-stage revision for
chronic PJIs that requires multiple surgeries, extended hospitalization, and months
of functional impairment, while still failing in over 10% of cases. The economic
burden is staggering, with per-patient costs in the U.S. frequently surpassing $
390,000. Compounding the challenge, the rising volume of joint replacements is driving
a steep increase in PJI incidence; by 2035, an estimated 425,800 new PJI cases are
expected globally—including 86,500 in China.

**Phase IIa Proof-of-Concept Trial Results**

This Phase IIa POC clinical trial, conducted in China, evaluated IA administration
of TNP-2092 plus systemic antibiotic background therapy—without debridement or joint
replacement—in patients with early or acute PJIs. Patients with chronic PJI requiring
long-term antibiotic suppression therapy were also included in the study.

As of July 1, 2026, data lock point (DLP) for interim analysis: 10 patients were
enrolled. Seven patients with culture- or next-generation sequencing (NGS)-confirmed
Gram-positive infections were included in the efficacy analysis. Two patients were
excluded from the efficacy analysis due to culture-negative results. One patient
had been newly enrolled as of the DLP, with efficacy data not yet available.

**Efficacy:** Among the five patients with early or acute PJI who received TNP-2092
IA, all had completed the 6-month follow-up, with 100% (5/5) treatment success reported.
Among the four patients who had completed the 12-month follow-up, 100% (4/4) treatment
success was reported. Of the two patients with chronic PJI who received TNP-2092
IA and had completed the 6-month follow-up, 50% (1/2) treatment success was reported;
12-month follow-up data were pending as of the DLP.

**Safety:** Nine patients were included in the safety analysis, with no TNP-2092-
related treatment-emergent adverse events (TEAEs) or serious adverse events (SAEs)
reported. The remaining patient, still undergoing follow-up, also reported no TNP-
2092-related TEAEs or SAEs as of the DLP.

These topline results demonstrate promising efficacy and a favorable safety profile
for TNP-2092 IA, supporting the accelerated clinical development of this novel non-
surgical approach to PJI treatment.

**Multicenter Phase IIb Trial Initiated**

A multicenter Phase IIb clinical trial to further evaluate TNP-2092 IA has received
approval from China’s National Medical Products Administration (NMPA), and the trial
has recently been initiated.

**Expert Commentary**

**Professor Li Cao**, Chief Physician at the Orthopedics Center of the First Affiliated
Hospital of Xinjiang Medical University, and the Principal Investigator for the 
POC trial:

"PJI is a devastating condition, and currently, patients have very limited treatment
options. TNP-2092 represents a paradigm shift in PJI therapy. The combination of
TNP-2092, a novel biofilm-eradicating agent with intra-articular delivery offers
the potential to cure PJI without subjecting patients to the painful, prolonged,
and costly surgical pathway. I am extremely excited to see patients in this trial
achieve cure—sparing them from the grueling surgical journey they would otherwise
face."

**Professor Javad Parvizi, MD, FRCS**, Professor of Orthopedic Surgery, Acibadem
University, Istanbul, past president of the American Association of Hip and Knee
Surgeons, and Co-Chair, International Consensus Meeting (ICM) on PJI:

"Orthopedic surgery has seen remarkable breakthroughs that have changed countless
lives—yet the management of PJI has remained stubbornly stagnant. The field is in
urgent need of truly transformative innovation. I am excited by the proof-of-concept
data for TNP-2092, which I believe has the potential to dramatically improve outcomes
and quality of life for PJI patients."

**About Rifaquizinone (TNP-2092)**

TNP-2092 is a first-in-class, triple-targeting drug candidate specifically engineered
to address the critical unmet need in implant-associated biofilm infections. Its
distinct mechanism of action synergistically inhibits bacterial RNA polymerase, 
DNA gyrase, and topoisomerase IV—a triple-targeting approach that not only confers
potent activity against resistant pathogens, including Methicillin-resistant _Staphylococcus
aureus_ (MRSA) and Quinolone-resistant _S. aureus_ (QRSA), but also drives an exceptionally
low resistance frequency of <10⁻¹².

TNP-2092 has demonstrated potent biofilm bactericidal activity in both _in vitro_
and _in vivo_ models, outperforming current standard-of-care antibiotics. The company
has successfully completed six Phase I and Phase II clinical trials in the United
States and China, with TNP-2092 showing a favorable safety profile and excellent
efficacy against acute bacterial skin and skin structure infections (ABSSSI).

The U.S. Food and Drug Administration has granted TNP-2092 Qualified Infectious 
Disease Product (QIDP), Fast Track, and Orphan Drug designations for the treatment
of PJI. Additionally, TNP-2092 received the Excellence Award at China’s National
Disruptive Technology Innovation Competition.

**About TenNor Therapeutics**

TenNor Therapeutics is a near-commercial-stage biotechnology company dedicated to
the discovery, development, and commercialization of differentiated therapies to
address unmet medical needs in disease areas associated with bacterial infections
and bacterial metabolism. Empowered by its proprietary multi-targeting conjugate
molecule technology, TenNor Therapeutics aims to deliver the best therapeutic solutions
to overcome the limitations of conventional treatments and improve patient outcomes.

As of June 30, 2026, TenNor Therapeutics had built a pipeline of eight innovative
programs, including two Core Products: **Rifasutenizol (TNP-2198)** – a new molecular
entity (NME) drug candidate used as part of a triple therapy for the treatment of
_Helicobacter pylori_ (_H. pylori_) infection. **Rifaquizinone (TNP-2092)** – a 
triple-targeting antibacterial drug candidate for the treatment of implant-associated
bacterial infections, including periprosthetic joint infection (PJI), left ventricular
assist device infection (LVADI), and catheter-related bloodstream infection (CRBSI).

**Forward-Looking Statements**

This press release contains forward-looking statements regarding TenNor Therapeutics’
product development, clinical trial plans, and regulatory pathways. Actual results
may differ materially due to various risks and uncertainties. TenNor undertakes 
no obligation to update these statements except as required by law.

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [TenNor Therapeutics Reports Positive Phase IIa POC Data for Rifaquizinone (TNP-2092), the First Non-Surgical Therapy Candidate for Periprosthetic Joint Infection ](http://www.prnasia.com/story/archive/5042135_CN42135_0?rand=184833)